AI Science Tracker
EN

Laboratori Vita

1 discovery from 2022

Discoveries

Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers

Source check: Source checked. Not independent scientific confirmation.

Finding: A feature-selection and decision-tree pipeline prioritized TOP1, PDIA4 and OGN as candidate high-grade serous ovarian cancer markers. The classifier reported 98.1% accuracy in repeated CPTAC cross-validation and 97.2% tumor sensitivity in a separate TCGA dataset; assay validation and clinical utility were not shown.

Technology: Machine-learning feature selection and decision-tree classification of HGSOC proteomic data

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Feature selection and decision-tree classification prioritize protein features from high-grade serous ovarian cancer proteomic measurements.
Test and result
A three-protein classifier reported 98.1% accuracy in repeated five-fold validation and 97.2% tumor sensitivity on the separate TCGA dataset.
Limitation / still unknown
The authors present candidate biomarkers; no serum assay or prospective clinical utility is demonstrated.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8866540/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary full-text Methods and Results; bibliographic date and duplicate check reviewed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.